Abstract: The invention provides novel compounds having the general formula I: wherein R1, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.
Abstract: Various amide compounds that bind Cbl-B, including those that are selective for C-Cbl, and methods of making and using the same.
Type:
Application
Filed:
February 3, 2022
Publication date:
September 12, 2024
Applicant:
Genentech, Inc.
Inventors:
Jun Liang, Araz Jakalian, Michael John Lambrecht, Robin Larouche-Gauthier, Malcolm Huestis, Man Un Ung, Xiaojing Wang, Arun Yadav, Jason Robert Zbieg, Fabio Broccatelli
Abstract: This invention pertains to fused ring compounds of Formula (I), as further detailed herein, which are used for the inhibition of Ras proteins, as well as compositions comprising these compounds and methods of treatment by their administration.
Type:
Grant
Filed:
December 17, 2021
Date of Patent:
September 10, 2024
Assignee:
Genentech, Inc.
Inventors:
Sushant Malhotra, Jianfeng Xin, Steven Do, Jack Terrett
Abstract: Provided herein are combination therapies comprising an ATP competitive AKT inhibitor, fulvestrant, and CDK4/6 inhibitor for use in treating hormone receptor positive and HER2 negative locally advanced unresectable or metastatic breast cancer.
Abstract: Improved methods of synthesis of a restrained complexing agent are described herein. Compounds, including salts and solvates thereof, and compositions relevant to the improved methods are also described.
Abstract: The present disclosure relates, inter alia, to complexes of the Na+ leak channel non-selective protein (NALCN) with FAM155A (also called FAM155; Family with sequence similarity 155 member A), UNC79 (uncoordinated 79), and UNC80 (uncoordinated 80), methods of screening for molecules that modulate the activity of the complex, and identified modulators thereof.
Type:
Application
Filed:
January 5, 2024
Publication date:
September 5, 2024
Applicants:
Genentech Inc., University of Copenhagen
Inventors:
Jian Mehr-Dean Payandeh, Stephan Alexander Pless, Han Chow Chua, Marc Kschonsak
Abstract: The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of cancer (e.g., kidney cancer (e.g., renal cell carcinoma (RCC)), lung cancer (e.g., non-small cell lung cancer (NSCLC)), bladder cancer (e.g., urothelial bladder cancer (UBC)), liver cancer (e.g., hepatocellular carcinoma (HCC)), ovarian cancer, or breast cancer (e.g., triple-negative breast cancer (TNBC))). The invention is based, at least in part, on the discovery that expression levels of one or more biomarkers described herein in a sample from an individual having cancer can be used in methods of predicting the therapeutic efficacy of treatment with a VEGF antagonist (e.g., an anti-VEGF antibody, (e.g., bevacizumab) or a VEGFR inhibitor (e.g., a multi-targeted tyrosine kinase inhibitor (e.g., sunitinib, axitinib, pazopanib, or cabozantinib))) and a PD-L1 axis binding antagonist (e.g., a PD-L1 binding antagonist (e.g., anti-PD-L1 antibody, e.g.
Abstract: Described herein are phenoxy-pyridyl-pyrimidine compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I structure or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
Type:
Grant
Filed:
September 12, 2019
Date of Patent:
August 27, 2024
Assignee:
Genentech, Inc.
Inventors:
Marie-Gabrielle Braun, Cuong Q. Ly, Georgette Castanedo, Paul Gibbons, Wendy Lee, Joachim Rudolph, Nicole Alice Blaquiere, Jacob Bradley Schwarz, Ramsay Beveridge, Jean-Philippe Leclerc, Alexandre Lemire, Leo Fu
Abstract: Provided herein are methods to synthesize compounds useful in the treatment of cancer where such compounds comprise a quinazolinyl core moiety and at least one stereoisomeric or atropisomeric moiety.
Type:
Grant
Filed:
February 3, 2023
Date of Patent:
August 27, 2024
Assignees:
Genentech, Inc., Hoffmann-La Roche Inc.
Inventors:
Rene Lebl, Ngiap Kie Lim, Roland Christoph Meier, Ugo Jonathan Orcel, Joerg Sedelmeier, Jeff Shen, Lauren Elizabeth Sirois, Jacob C. Timmerman, Etienne Trachsel, Nicholas Andrew White, Jie Xu, Haiming Zhang, Stephan Bachmann, Thomas Michael Bass, Raphael Bigler, Johannes Adrian Burkhard, Kyle Bradley Pascual Clagg, Francis Gosselin, Chong Han, Dainis Kaldre, Sean M. Kelly, Sebastian Herold, Christian Leitner
Abstract: The present invention provides a cell-based assay for identifying and/or quantifying anti-CD3 homodimers in a composition comprising a T cell-dependent Bispecific antibody (TDB). In some aspects, the invention T cells comprising a T cell activation responsive reporter are contacted with the TDB to detect the presence of anti-CD3 homodimers. Compositions of reporter T cells and kits are also contemplated.
Abstract: The present invention relates to a method of developing purification processes for antibody drug conjugates using cation-exchange chromatography in flow-through mode leveraging the purification conditions of the antibody intermediate without a change to the critical quality attributes (CQA) of the ADC.
Type:
Application
Filed:
August 22, 2022
Publication date:
August 22, 2024
Applicant:
Genentech, Inc.
Inventors:
Rachel Hendricks, Matthew Henry Hutchinson, Mark Frederick Fedesco, Bejamin Phu Tran
Abstract: Provided herein are antibacterial compound peptides active against Gram-negative bacteria. In various embodiments, the compounds act by inhibition of BAM A membrane protein. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
Type:
Application
Filed:
June 1, 2022
Publication date:
August 22, 2024
Applicant:
Genentech, Inc.
Inventors:
Christian Nathaniel CUNNINGHAM, Jian Mehr-Dean PAYANDEH, Steven Thomas RUTHERFORD, Kelly Marie Colvin STOREK, Patrick C. REID, Hayato YANAGIDA, Junichi NISHIKAWA
Abstract: The present invention is directed to a combination therapy involving an anti-HER2 antibody-drug conjugate and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a HER2-expressing cancer.
Type:
Application
Filed:
May 9, 2024
Publication date:
August 22, 2024
Applicant:
GENENTECH, INC.
Inventors:
Gail Lewis Phillips, Deepak Sampath, Ingrid Wertz
Abstract: The present disclosure relates to a deep learning neural network that can identify corpora lutea in the ovaries and a rules-based technique that can count the corpora lutea identified in the ovaries and infer an ovarian toxicity of a compound based on the count of the corpora lutea (CL). Particularly, aspects of the present disclosure are directed to obtaining a set of images of tissue slices from ovaries treated with an amount of a compound; generating, using a neural network model, the set of images with a bounding box around objects that are identified as the CL within the set of images based on coordinates predicted for the bounding box; counting the bounding boxes within the set of images to obtain a CL count for the ovaries; and determining an ovarian toxicity of the compound at the amount based on the CL count.
Abstract: Heteroaryl pyridone and aza-pyridone compounds are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using heteroaryl pyridone and aza-pyridone compounds for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
Type:
Application
Filed:
November 29, 2023
Publication date:
August 15, 2024
Applicant:
Genentech, Inc.
Inventors:
James John CRAWFORD, Daniel Fred ORTWINE, BinQing WEI, Wendy B. YOUNG
Abstract: Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.
Type:
Application
Filed:
April 5, 2024
Publication date:
August 15, 2024
Applicants:
Genentech, Inc., Hoffmann-La Roche Inc.
Inventors:
Jennifer Eng-Wong, Whitney Kirschbrown, Tarik Ali Khan, Jasper Lin, Sreedhara Alavattam, Amit Garg, Sarah Heeson, Tanja Badovinac-Crnjevic, Christine Wurth
Abstract: Provided herein are combinations comprising: (i) one or more EGFR inhibitors; and (ii) one or more PERK activators, such as the specific EGFR inhibitors and PERK activators described herein. Also provided herein are methods of treating cancer in a subject in need thereof, comprising administering to the subject an effective amount of such combinations.
Abstract: A composition comprising a main species HER2 antibody that binds to domain II of HER2 and acidic variants thereof is described. Pharmaceutical formulations comprising the composition, and therapeutic uses for the composition are also disclosed.
Abstract: The present disclosure provides methods for treating lung cancer (such as small cell lung cancer, e.g., extensive stage small cell lung cancer) in an individual. The methods comprise administering to the individual a PD-1 axis binding antagonist (such as an anti-PD-L1 antibody, e.g., atezolizumab), a platinum agent (e.g., cisplatin or carboplatin), and a topoisomerase II inhibitor (e.g., etoposide).
Type:
Application
Filed:
August 2, 2023
Publication date:
August 8, 2024
Applicant:
Genentech, Inc.
Inventors:
Ariel LOPEZ-CHAVEZ, Daniel Antonius WATERKAMP
Abstract: Provided are, inter alia, multispecific antigen binding proteins, or antigen-binding fragments thereof, comprising one or more mutations in the VH/VL domains and/or CH1/CL domains, pharmaceutical compositions comprising same, isolated nucleic acids, vectors, and host cells encoding/expressing same, method of making the multispecific antigen binding proteins, computer readable media for evaluating multispecific antigen binding proteins, and libraries.
Type:
Grant
Filed:
August 5, 2021
Date of Patent:
August 6, 2024
Assignee:
Genentech, Inc.
Inventors:
Paul Carter, Christoph Spiess, Yiyuan Yin, Jianhui Zhou, Wendy Sandoval, Jacob Corn, Michael Dillon